---
schema_version: "secwatch.filing_event.v1"
accession: "0001528287-23-000005"
form_type: "8-K"
ticker: "NPCE"
cik: "0001528287"
company_name: "NeuroPace Inc"
filed_at: "2023-03-02T23:59:59+00:00"
generated_at: "2026-06-18T15:02:38.899633+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# NeuroPace Q4 revenue $12.8M (+16% YoY); guides FY2023 revenue $50-52M

## Summary
- Q4 2022 revenue $12.8M (+16% YoY); initial implant revenue $9.8M (+15% YoY).
- Full year 2022 revenue $45.5M (+1% YoY); net loss $47.1M vs $36.1M in 2021.
- FY2023 guidance: revenue $50-52M (10-14% growth), gross margin 69-71%, op expenses $75-77M.
- DIXI Medical distribution contributed $1.6M in Q4; NAUTILUS study for primary generalized epilepsy ongoing.
- Cash burn reduced to ~$15M in H2 2022 from ~$23M in H1; cash $77.4M at year-end.

## SEC filing metadata
- accession: 0001528287-23-000005
- form_type: 8-K
- ticker: NPCE
- cik: 0001528287
- company_name: NeuroPace Inc
- filed_at: 2023-03-02T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1528287/000152828723000005/0001528287-23-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1528287/000152828723000005/npce-20230302.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001528287-23-000005
- JSON: https://secwatch.observer/filing/0001528287-23-000005.json
- Plain text: https://secwatch.observer/filing/0001528287-23-000005.txt

## Key facts
- Earnings Releases
  NeuroPace Inc updated its Full Year 2023 guidance (initiated).
  - Period: Full Year 2023
  - Guidance: initiated
  - Result: guidance update
  source text: Full Year 2023 Financial Guidance • Total revenue to range between $50.0 million to $52.0 million, growing approximately 10% to 14% over 2022 • Gross margin to range between 69% to 71% • Total operating expenses to range between $75.0 million to $77.0 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1528287/000152828723000005/0001528287-23-000005-index.htm
- Earnings Releases
  NeuroPace Inc reported the full year ended December 31, 2022 results: EPS not provided.
  - Period: the full year ended December 31, 2022
  - EPS: not provided
  - Result: reported results
  source text: On March 2, 2023, NeuroPace, Inc. issued a press release announcing its financial results for the fiscal quarter and full year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1528287/000152828723000005/0001528287-23-000005-index.htm
- Earnings Releases
  NeuroPace Inc reported the full year ended December 31, 2022 results: EPS not provided.
  - Period: the full year ended December 31, 2022
  - EPS: not provided
  - Result: reported results
  source text: Total revenue was $45.5 million in 2022, representing growth of 1% compared to 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1528287/000152828723000005/0001528287-23-000005-index.htm
- Earnings Releases
  NeuroPace Inc reported the full year ended December 31, 2022 results: EPS not provided.
  - Period: the full year ended December 31, 2022
  - EPS: not provided
  - Result: reported results
  source text: Net loss was $47.1 million for 2022, compared to a net loss of $36.1 million in 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1528287/000152828723000005/0001528287-23-000005-index.htm
- Earnings Releases
  NeuroPace Inc reported the fourth quarter ended December 31, 2022 results: EPS not provided.
  - Period: the fourth quarter ended December 31, 2022
  - EPS: not provided
  - Result: reported results
  source text: On March 2, 2023, NeuroPace, Inc. issued a press release announcing its financial results for the fiscal quarter and full year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1528287/000152828723000005/0001528287-23-000005-index.htm
- Earnings Releases
  NeuroPace Inc reported the fourth quarter ended December 31, 2022 results: EPS not provided.
  - Period: the fourth quarter ended December 31, 2022
  - EPS: not provided
  - Result: reported results
  source text: Total revenue was $12.8 million in the fourth quarter of 2022, representing growth of 16% compared to the prior year period and 15% compared to the prior quarter.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1528287/000152828723000005/0001528287-23-000005-index.htm
- Earnings Releases
  NeuroPace Inc reported the fourth quarter ended December 31, 2022 results: EPS not provided.
  - Period: the fourth quarter ended December 31, 2022
  - EPS: not provided
  - Result: reported results
  source text: Net loss was $11.1 million for the fourth quarter of 2022, compared to a net loss of $10.7 million in the prior year period.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1528287/000152828723000005/0001528287-23-000005-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.